Melanoma treatment options 1 step closer

Key points
- A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.
- U of A chemistry professor Dennis Hall said after three years of work, his research team has successfully produced the substance called Palmerolide A.
- "The potency of palmerolide is exceptional and melanoma is a very aggressive cancer for which there is almost no chemotherapeutic recourse," said Hall.
- "Current chemotherapy as an overall strategy is not very effective in treating melanoma.
A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.
U of A chemistry professor Dennis Hall said after three years of work, his research team has successfully produced the substance called Palmerolide A.
"The potency of palmerolide is exceptional and melanoma is a very aggressive cancer for which there is almost no chemotherapeutic recourse," said Hall. "Natural substances like palmerolide offer real hope for such treatments.
"Current chemotherapy as an overall strategy is not very effective in treating melanoma. Less than a quarter of patients respond to chemotherapy and it typically only works for less than a year, and it has little to no effect on survival time. Palmerolide A as a targeted therapy may prove to be more effective [for treatment] with less toxicity," said Hall.
"One of the problems with most cancer drugs is the lack of selectivity for cancer cells versus normal cells. Preliminary data for Palmerolide A looks very promising in terms of solving this issue," he said.
"For commercialization, the structure needs to be made more 'drug-like;' smaller and more water-soluble, while preserving the potency," said Hall, who is optimistic that his U of A team is moving forward in the race to develop a treatment for melanoma.
###
Hall's research findings were recently published in the Journal of the American Chemical Society.
Dennis Hall is available for interviews on Wednesday, Oct. 21. Please Contact Wanda Vivequin..
Contact: Wanda Vivequin
wanda.vivequin@ualberta.ca
780-492-4073
University of Alberta
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNew genetic mutation identified in melanoma cancer cells
There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal and breast cancer, and now melanoma. A new study has revealed that a genetic…
3 September 2015
NewsMoffitt makes important steps toward developing a blood test to catch pancreatic cancer early
Pancreatic cancer is the fourth most common cause of cancer-related death in the United States and has a 5-year survival rate of only 6 percent, which is the lowest rate of all types of cancer according to the American…
29 August 2015
NewsA better way to personalize bladder cancer treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. In early proof-of-concept research, the team took…







